Cancure
  • About
    • Vision
    • Board & Management
    • Scientific Advisors
  • Cancer
    • Current Treatments
    • Market
  • Therapies
    • Genvax – lead candidate CNC118
    • Galectin – lead candidate CNC225
    • Mitocans – lead candidate CNC332
    • Combination Therapy
    • Genvax vs. CAR-T
    • Development Program
    • References
  • Investors
    • Investors Snapshot
    • Public Documents
    • News
  • Contact
  • Search
Cancer Treatments
Galectin
Mitocans
Mitocans

NousCom receives $49M to trial off-the-shelf cancer vaccine

AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans

Incyte pays MacroGenics $150M for PD-1 inhibitor

Gilead buys CAR-T developer Kite Pharma for $12B

Bone marrow cancer and immuno-oncology research agreement

Servier, Pieris launch up to $1.8B immuno-oncology alliance

Roche bets up to $1B on Blueprint's immunomodulation platform

Lilly signs a $1B deal to deepen its oncology ties with China's Innovent

Novartis inks a string of deals to widen its immuno-oncology arsenal

PreviousNext

“Cancure’s mission is to develop breakthrough drugs that push the limits of anti-cancer response rates, and hasten the evolution of cancer treatments into cancer cures.”

Cancure is a biopharmaceutical company founded in 2012, with the aim of investing in therapies capable of countering several major diseases afflicting society today.

Cancure has developed a suite of breakthrough oncology therapies, which employ innovative methods to enhance the body’s anti-cancer immune response, or kill cancer cells by exploiting novel targets within them. These revolutionary therapies are ideally positioned in the emerging fields of immuno-oncology, combination therapies and mitochondrial biology.

Cancure is developing these therapies into marketable drugs that push the limits of anti-cancer response rates and hasten the evolution of cancer treatments into cancer cures.

Genvax

GENVAX

Galectin

GALECTIN INHIBITORS

Mitocans

MITOCANS

News

  • NousCom receives $49M to trial off-the-shelf cancer vaccine November 9, 2017
  • AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans November 1, 2017
  • Incyte pays MacroGenics $150M for PD-1 inhibitor October 26, 2017
  • Gilead buys CAR-T developer Kite Pharma for $12B August 29, 2017

Contact

Mr Craig Miles
craig@cancure.com
+61 (0) 408 778 797
PO Box 1177, Broadbeach,
Queensland, Australia 4218

Copyright © 2015 All rights reserved.
Scroll to top